Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation.
Surya P BhattKlaus F RabeNicola A HananiaClaus F VogelmeierMona BafadhelStephanie A ChristensonAlberto PapiDave SinghElizabeth LawsNaimish PatelGeorge D YancopoulosBolanle AkinladeJennifer MaloneyXin LuDeborah BauerAshish BansalRaolat M AbdulaiLacey B Robinsonnull nullPublished in: The New England journal of medicine (2024)
In patients with COPD and type 2 inflammation as indicated by elevated blood eosinophil counts, dupilumab was associated with fewer exacerbations and better lung function than placebo. (Funded by Sanofi and Regeneron Pharmaceuticals; NOTUS ClinicalTrials.gov number, NCT04456673.).